Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H31NO5 |
| Molecular Weight | 401.4959 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)COC1=CC(C)=C(CCN[C@@H](C)[C@H](O)C2=CC=C(O)C=C2)C=C1C
InChI
InChIKey=SLXOKVKOBXCWCK-SBUREZEXSA-N
InChI=1S/C23H31NO5/c1-5-28-22(26)14-29-21-13-15(2)19(12-16(21)3)10-11-24-17(4)23(27)18-6-8-20(25)9-7-18/h6-9,12-13,17,23-25,27H,5,10-11,14H2,1-4H3/t17-,23-/m0/s1
Ritobegron (KUC 7483) is a selective β3-adrenoceptor agonist that was developed for oral treatment of overactive bladder. It is the prodrug of the active compound KUC-7322. Phase I studies have investigated the pharmacodynamic and pharmacokinetic effects of ritobegron in healthy individuals and patients with spinal cord injury. Ritobegron exhibits a high selectivity for the bladder versus other organs, and decreased intravesical pressure with minimal effects on the cardiovascular system in rats. When administered in combination with organic anion transporter (OAT) inhibitors such as probenecid (primarily used in treating gout and hyperuricemia), the plasma concentration of the active compound KUC-7322 may increase.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID30180263
Created by
admin on Mon Mar 31 21:30:07 GMT 2025 , Edited by admin on Mon Mar 31 21:30:07 GMT 2025
|
PRIMARY | |||
|
E89L9L8KFH
Created by
admin on Mon Mar 31 21:30:07 GMT 2025 , Edited by admin on Mon Mar 31 21:30:07 GMT 2025
|
PRIMARY | |||
|
9810282
Created by
admin on Mon Mar 31 21:30:07 GMT 2025 , Edited by admin on Mon Mar 31 21:30:07 GMT 2025
|
PRIMARY | |||
|
255733-81-4
Created by
admin on Mon Mar 31 21:30:07 GMT 2025 , Edited by admin on Mon Mar 31 21:30:07 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD
